Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
101 Cards in this Set
- Front
- Back
Chemical elements used with lasers
and may be combined and abbreviated in laser references |
aluminum, argon, chromium, erbium, garnet, helium, holmium, neodymium, rhodamine, ruby, thulium, yttrium
|
|
amino acids of proteins
|
phenylalanine Phe, F
proline Pro, P tryptophan Trp, W |
|
bases and nucleosides
|
cytosine Cyt
purine Pur uracil Ura |
|
common ribonucleosides
|
adenosine Ado, A
cytidine Cyd, C uridine Urd, U |
|
sugars and carbohydrates
|
fructose Fru
glucose Rib |
|
Drug development
|
Phase 1: Studies conducted in healthy volunteers to assess safety, effects, metabolism, kinetics, and drug interactions
|
|
Drug development
|
Phase 2: Studies conducted to establish therapeutic efficacy and determine dose range.
|
|
Drug development
|
Phase 3: Trials typically randomized, controlled studies that assess safety/efficacy in a large sample of patients (2000-3000) for whom the drug is anticipated to be effective.
|
|
Brand name drug
|
manufacturer's name, same as a trademark name.
|
|
Trade name
|
broader term than trademark, identifying the manufacturer, not the product.
|
|
Code name
|
temporary designation for an as-yet-unnamed drug, assigned by the manufacturer. May include a code number or code designation.
|
|
Chemical name
|
Describes the chemical structure of a drug
|
|
Brand name
|
Proprietary name, manufacturer's name for a drug, same as trademark name
|
|
Generic name
|
nonproprietary name, official drug name. Created by US Adopted Names Council (USAN). Ensures consistent usage and nonduplication.
|
|
DEA
|
Drug Enforcement Administration
|
|
Drugs of Abuse Scheduling
|
Schedule I: Drugs deemed to have a high risk for abuse/dependence for which there is no current recognized clinical application/use.
Ex. PCP, heroin, LSD, marijuana |
|
Drugs of Abuse Scheduling
|
Schedule II. Drugs deemed to have a high risk for abuse/dependence that also have current clinical applications.
Ex. opium, morphine, cocaine |
|
Drugs of Abuse Scheduling
|
Schedule III: Drugs deemed to have some risk for abuse/dependence that also have a high degree of clinical application/use. Ex amphetamine, Valium, codeine
|
|
Drugs of Abuse Scheduling, -barbital
|
Schedule IV: Drugs deemed to have a limited risk for abuse/dependence that also have a high degree of clinical application/use. Ex. chloral hydrate, phenobarbital, barbiturate, , ex. butabarbital, pentobarbital
|
|
Drugs of Abuse Scheduling
|
Schedule V: Drugs deemed to have a low risk for abuse/dependence that are used for clinical research or represent the above drugs used in limited amounts for specific applications.
|
|
Dose
|
amount to be administered at one time or total amount administered
|
|
Dosage
|
regimen expressed as a quantity per unit of time
|
|
a.c.
|
ante cibum (before food)
|
|
b.i.d.
|
bis in die (twice a day)
|
|
gtt.
|
guttae (drops)
|
|
n.p.o.
|
nil per os (nothing by mouth)
|
|
n.r.
|
non repetatur (do not repeat)
|
|
p.c.
|
post cibum (after food)
|
|
p.o.
|
per os (by mouth)
|
|
p.r.n.
|
pro re nata (as needed)
|
|
q.4 h.
|
quaque 4 hora (every 4 hours)
|
|
q.h.
|
quaque hora (every hour)
|
|
q.i.d.
|
quater in die (4 times a day)
|
|
t.i.d.
|
ter in die (3 times a day)
|
|
u.d.
|
ut dictum (as directed)
|
|
USP
|
United States Pharmacopeia
|
|
hypothalmic hormones that stimulate the release of pituitary hormones (suffix)
|
relin
|
|
hypothalmic hormones that inhibit the release of pituitary hormones (suffix)
|
relix
|
|
TRH
|
thyrotropin-releasing hormone
|
|
LHRH
|
luteinizing hormone-release hormone
|
|
GnRH
|
gonadotropin-releasing hormone
|
|
GHRF
|
growth hormone-releasing factor (somatorelin)
|
|
GHRIF
|
growth hormone release-inhibiting factor (detirelix acetate)
|
|
growth hormone ( suffix som-)
|
somatrem,somidobove, sometribove, somagrebove, somalapor, somenopor, sometripor, somfasepor
|
|
T4
|
levorotatory thyroxine
|
|
T3
|
tridothyronine
|
|
dextorotatory triiodothyronine
|
dextrothyroxine sodium
|
|
liothyronine and levothyroxine sodium
|
liotrix sodium
|
|
human insulin
|
derived from human DNA
human insulin injection (Humulin) |
|
porcine insulin
|
synthetic type of insulin, generally modified
|
|
human insulin injection
nonproprietary name expressed in % in combination form |
Humulin
proprietary name expressed with virgule (?) in combination form |
|
insulin lispro injection
nonproprietary name expressed in % in combination form |
Humalog
proprietary name expressed with virgule (?) in combination form |
|
insulin aspart injection
nonproprietary name expressed in % in combination form |
NovoLog
proprietary name expressed with virgule (?) in combination form |
|
insulin glargine injection
nonproprietary name expressed in % in combination form |
Lantus
proprietary name expressed with virgule (?) in combination form |
|
prompt insulin zinc suspension
nonproprietary name expressed in % in combination form |
Emilente
proprietary name expressed with virgule (?) in combination form |
|
insulin zinc suspension
nonproprietary name expressed in % in combination form |
Lente
proprietary name expressed with virgule (?) in combination form |
|
extended human insulin zinc suspension
nonproprietary name expressed in % in combination form |
Ultralente
proprietary name expressed with virgule (?) in combination form |
|
insulin isophane suspension
nonproprietary name expressed in % in combination form |
NPH
proprietary name expressed with virgule (?) in combination form |
|
Interferons
|
glycoproteins that exert antineoplastic, antiviral, and immuno-modulating effects
|
|
general classes of compounds or single compounds of interferons
|
interferon alfa or IFN-greek symbol
interferon beta or IFN-greek symbol interferon gamma or IFN-greek symbol |
|
individual, pure, identifiable compound interferons
|
expressed as:
ex. interferon alfa-2a |
|
mixtures of interferons from natural sources
|
expressed as:
interferon alfa-n1 |
|
Interlukens
|
class of proteins secreted mostly by macrophages and T lymphocytes. They induce growth and differentiation of lymphocytes and hematopoietec stem cells
|
|
interleukin 1 derivatives
|
nakin
|
|
interleukin 1a derivatives
|
onkain
|
|
interleukin 1b derivatives
|
benakin
|
|
interleukin 2 derivatives
|
leukin
|
|
interleukin 4 derivatives
|
trakin
|
|
interleukin 5 derivatives
|
penkin
|
|
interleukin 6 derivatives
|
exakin
|
|
interleukin 7 derivatives
|
eptakin
|
|
interleukin 8 derivatives
|
octakin
|
|
interleukin 9 derivatives
|
nonakin
|
|
interleukin 10 derivatives
|
decakin
|
|
interleukin 11 derivatives
|
elvekin
|
|
interleukin 12 derivatives
|
dodekin
|
|
interleukin 3 derivatives
(colony stimulating factors) |
plestim
|
|
colony-stimulating factors
|
naturally occurirng glycoproteins that regulate proliferation, differentiation, and maturation of hematopoietic growth factors.
|
|
cytokines
|
soluble immune system proteins
|
|
Granulocyte colony-stimulating factors (G-CSFs)
|
suffix grastim
ex. filgrastim, lenograstim, Pd-grastim |
|
Granulocyte-macrophage colony-stimulating factors (GM-CSFs)
|
suffix -gramostim
ex: ecogramostim molgramostim regramostim sargarmostim |
|
Macrophage colony-stimulating factors (M-CSFs)
|
suffix -mostim
ex: climostim lanimostim mirimostim |
|
Interleukin 3 (IL-3)
|
suffix - plestm
ex: muplestim daniplestim |
|
combined forms or conjugates of 2 types of colony-stimulating factors
|
suffix -distim
ex: leridistim milodistim |
|
stem-cell stimulating factors (SCSFs)
|
suffix -cestim
|
|
erythropoietin blood factors
|
suffix -poietin
add alfa, beta, or gamma to designate preparations with variable composition and carbohydrate activity. |
|
Isotopes
|
atoms of the same element with different atomic masses used in reference to radioactive drugs
ex. iodine 128, technetium 99m |
|
multi-drug regimens indicated by protocol designations or protocol acronyms (common in oncology and immunology)
|
ex. MOPP (methotrexate, vincristine sulfate, prednisone, and procarbazine)
|
|
Some chemotherapy protocols combine abbreviations designating the type of cancer with treatment and drug abbreviations
|
ex.
BRAJCEF (BR = breast cancer, AJ = adjuvant therapy, C = cyclophosphamide, E = epirubicin, F = fluorouracil) LUAVPG (:I = lung, AV = advanced, P + platinum, G = gemcotabome) |
|
vitamin B1
|
thiamine hydorchloride
|
|
vitamin B2
|
ribovlavin
|
|
vitamin B6
|
pyridoxine hydrochloride
|
|
vitamin B12
|
cyanocobalamin
|
|
vitamin C
|
ascorbic acid
|
|
vitamin D
|
cholocalciferol
|
|
vitamin D2
|
ergocalciferol
|
|
vitamin D3
|
cholecalciferol
|
|
vitamin K1
|
phytonadione
|
|
vitamin K3
|
menadione
|
|
INN
|
international proprietary name
|
|
herbal medicines
|
named and referred to in literature either by their common names of the genus and species names
ex. saffron Crocus sativus (saffron) |